A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure

This single-center prospective clinical trial evaluated the combination of nivolumab plus bendamustine (NB) as a salvage regimen in classical Hodgkin lymphoma patients after failure of nivolumab monotherapy. A total of 30 patients received nivolumab (3 mg/kg) on D1,14 and bendamustine (90 mg/m(2)) o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lepik, Kirill V., Mikhailova, Natalia B., Kondakova, Elena V., Zalyalov, Yuri R., Fedorova, Liudmila V., Tsvetkova, Luibov A., Kotselyabina, Polina V., Borzenkova, Evgeniya S., Babenko, Elena V., Popova, Marina O., Darskaya, Elena I., Baykov, Vadim V., Moiseev, Ivan S., Afanasyev, Boris V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306298/
https://www.ncbi.nlm.nih.gov/pubmed/32647803
http://dx.doi.org/10.1097/HS9.0000000000000401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306298/
https://www.ncbi.nlm.nih.gov/pubmed/32647803
http://dx.doi.org/10.1097/HS9.0000000000000401

Ejemplares similares